Meeting - Latest News:

Read the 3rd SARS-CoV-2 Update Meeting Report Here

 

 IABS Success Stories

 

Discover IABS success stories

 

 See every IABS conferences since year 2000

 

If you would like to join IABS, click here to see the online and offline application form.

Upcoming events and News

6th STATISTICS WORKSHOP - SUMMARY

Approaches for Improving Statistical Partnership in CMC Development, Manufacturing, and Regulation of Biologicals was the 6th meeting in the series of IABS workshops focusing on Statistics and the role they play in the development of biotherapeutics and vaccines.

Read the Summary of the Meeting

Meeting rescheduled - New Date Soon

Cross learning experience human and animal vaccine licensure
based on technology platforms

A Joint CEPI / IABS-EU Workshop

Registration and information about the Meeting

 

MEETING RESCHEDULED


The difficult situation we are facing currently in Europe
and the uncertainties concerning the evolution

of the Covid-19 pandemic
has led us to once again postpone
the CEPI / IABS-EU Workshop.

More information will be posted shortly.


 

 

 

Use the buttons below if you would like to share this info :

Meeting rescheduled NEW DATE_September 14 - 16, 2021 - Munich, Germany

Autogenous Vaccines:
Quality of production and movement in a common market

Ludwig-Maximilians-University Munich

registration and information about the meeting

Use the buttons below if you would like to share this info :
Read more ...

Meeting rescheduled - New Date - June 8-9, 2021, Ottawa, Canada

Maintaining the quality of vaccines through the use of references standards
Current challenges and future opportunities

Due to the uncertainties concerning the evolution
of the Covid-19 pandemic, the meeting is once again rescheduled
and will now take place on

June 8-9, 2021

 Registration and information about the meeting

Use the buttons below if you would like to share this info :
Read more ...

In Brief

  • Board Transitions: Message from the President

    2020 will be marked as a memorable year with the retirement of several truly noteworthy members of the IABS Board of Directors.  In this message, I am pleased to spotlight exceptional Board members that I am proud to call friends and colleagues.  

    Earlier this year Dr. Tony Lubiniecki voluntarily stepped off the board to allow the selection and appointment of a new Alliance Treasurer.  In September, Drs. Elwyn Griffiths, Girish Vyas, and Daniel Gaudry will attend their final Board meeting in Ottawa, Canada.  Collectively they served approximately 112 years on the Board, and many more years in other leadership positions with IABS. Please read on for brief biographies of these 4 individuals that have served IABS so well in a variety of Alliance leadership positions. 

    read more

  • Accolades for IABS Member

    Long-term IABS Board of Directors Member and Alliance Treasurer Dr. Tony Lubiniecki was recently honored for his contributions to Chemistry, Manufacturing, and Controls Regulatory Science by CASSS.    CASSS is a California nonprofit corporation which exists to enable a global community of industry, academic and regulatory professionals to work together to resolve scientific challenges in their field. 

    Read more

  • 3rd Human Challenge Trials in Vaccine Development

    February 6-7, 2020
    Pembroke College
    Oxford, United Kingdom
    View the Summary of the Meeting

     

  • 1

Latest news

  • Accolades for IABS Member

    Long-term IABS Board of Directors Member and Alliance Treasurer Dr. Tony Lubiniecki was recently honored for his contributions to Chemistry, Manufacturing, and Controls Regulatory Science by CASSS.    CASSS is a California nonprofit corporation which exists to enable a global community of industry, academic and regulatory professionals to work together to resolve scientific challenges in their field. 

     

    “CASSS has honored Tony Lubiniecki, PhD with its prestigious Hancock Award for Outstanding Achievements in CMC Regulatory Science.  This annual award recognizes outstanding and sustained contributions in the field of regulatory science. Lubiniecki was announced as the 2020 honoree during CASSS’s 24th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products,  January 28-30, 2020 in Washington DC.”  Additional information on the award is located on the CASSS website:  https://www.casss.org/news/488524/Tony-Lubiniecki-Announced-as-CASSS-Hancock-Award-Winner-for-2020.htm

     

    CASSS has also recognized several other long-time IABS Members for their contributions to biological/regulatory science.  In 2014, Dr. Kathryn Zoon, https://www.casss.org/page/933?&hhsearchterms=%22awards%22 and in 2017, Dr. John Petricciani https://www.casss.org/page/Hancock2017?&hhsearchterms=%22petricciani%22 each received the received William Hancock Award for Outstanding Achievements in CMC Regulatory Science.

     

     

  • ADVAC 2020
    11 to 22 May, 2020
    Veyrier du Lac (near Annecy) France

    ADVAC 2020 is cancelled.

    Due to the increasing travel restrictions and flight cancellations caused by COVID-19 and considering the policies of the organizing institutions, co-sponsor institutions and their government/umbrella institutions, as well as individual discussions and interactions with a number of the ADVAC Scientific Committee and lecturers, the decision has been taken jointly by the Mérieux Foundation and the University of Geneva to cancel this year’s ADVAC

    The 21st ADVAC will now take place from 10 to 21 May 2021.  

  • In May 2019, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB).

    Read more

  • View the speaker slides from the 3Rs meeting, NIH, Bethesda : folder click here

    View the meeting webpage Here

    Report now available Here

     

  • IABS Presentation to the U.S. Veterinary Biologics Training Program

    In May 2018, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB).  The IICAB was founded in 1995 by the USDA Animal and Plant Health Inspection Service and Iowa State University. In June 1998, the IICAB received designation as a component of the World Organization for Animal Health (OIE) Collaborating Centre for the Diagnosis of Animal Diseases and Vaccine Evaluation in the Americas. The designation is shared with the USDA APHIS National Veterinary Services Laboratories (NVSL) and Center for Veterinary Biologics (CVB). 

    The first Veterinary Biologics Training Program was held in June 1996 at the ISU College of Veterinary Medicine. The training program has been offered each year since then. More than 2600 individuals have attended the program including over 740 international participants from 90 different countries. More than 150 participants attended in 2018.  The program is known worldwide as a premier training program in immunology and veterinary vaccines. Many individuals who have participated in the training continue to be actively involved with veterinary biologics issues and activities world-wide.

    Training Program participants were keenly interested in IABS and had many questions.  Complimentary IABS Membership for 2018-2019 was offered to participants.  IABS is looking forward to some of the new members attending upcoming conferences and workshops and becoming more actively involved with our organization.

    Respectfully submitted,

    Rick Hill, IABS Communication Committee Chair

  • IABS “3R” Conferences Highlighted in Presentation at the 10th World Congress on Alternatives and Animal Use in the Life Sciences.

    August 24, 2017, an overview of IABS’ “3R” Conferences, Symposia and Workshops was included in a presentation at the vaccine session at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle Washington (See Summary Slide below).  The World Congress are periodic scientific meetings with emphasis on the latest technologies for reduction and replacement of animals and innovations in approaches to ethics, animal welfare and public policy.   Interestingly, the World Congress’ first meeting was in 1993, within one year of the IABS’s first Langen Symposium.  The 11th World Congress is scheduled for 2020 in the Netherlands. 

    In general, World Congress participants were aware of IABS’ leadership in the “3R” and Animal “Alternatives” arena and several inquired about the status of future IABS conferences.   The meeting presented an opportunity to discuss IABS overall, but also the organizations strategic priority to host “3R” related meetings by the North American and European Affiliates.

    Respectfully submitted,

    Rick Hill, IABS Communication Committee Chair

     

  • IABS is pleased to announce a valuable new book written by Board Member Dr. Rebecca Sheets titled Fundamentals of Biologicals Regulation:  Vaccines & Biotechnology Medicines. Dec. 2017, published by Elsevier’s imprint Academic Press.

    For more information, please see https://www.elsevier.com/books/fundamentals-of-biologicals-regulation/sheets/978-0-12-809290-3

  • French speaking visitors can listen to the interviews of Dr. Stanley Plotkin and Dr. Marc Bonneville, during the IABS65 anniversary ceremony in Lyon

    The interviews are available here : https://www.lyondemain.fr/iabs-lyon-coronavirus-vaccins-standardisation-merieux-biologie-lyonbiopole-stanley-plotkin-marc-bonneville-maladies-infections-conference/

  • Job Opportunity

    Associate / Director CMC Statistician

    The CMC Statistician is a key member of the Technical Development organization responsible for supporting the integration of statistical strategy throughout CMC. In this role you will contribute directly to advancing Moderna’s portfolio of products from development to commercial manufacturing, and help build technical platforms for a rapidly expanding pipeline. You will collaborate as a key project resource and team member with scientists and engineers working on the forefront of mRNA science. You will design experiments and develop predictive models for technical processes and analytical methods.

    At Moderna we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.

    We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.

    LinkedIn => https://www.linkedin.com/jobs/view/2220730661/?refId=WDm3J%2FTPRoSWNZGCPHAWkA%3D%3D

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9

IABS-EU Heads Work Package in new IMI project: VAC2VAC

VAV2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the "Consistency Approach" for quality control of established vaccines, where current quality control approaches are often relying on in vivo methods.

VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with official medicines control laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physico-chemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the "Consistency Approach" for established vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.

Learn More

Press Release…

ZAPI

About ZAPI - The new Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases…

Learn more

 


IABS-EU is officially recognized by French authorities as a nonprofit organization.



Founding Members :

Read more:

International Alliance for Biological Standardization


Twitter Feed

Examples of networks to address transdisciplinary issues related to infectious disease prevention and vaccine devel… https://t.co/HmhZmZFHn9
#IABS 65 conference on Infectious diseases, LYON. John Edmunds (London School of Tropical Hygiene & Medicine): Real… https://t.co/TYd0mOS3zC
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.